The problem with adding fiber to food is that you can usually taste it. It creates a gritty texture, alters mouthfeel, or simply tastes like cardboard. For decades, that sensory penalty has been the primary barrier to closing what nutritionists call the “fiber gap” in modern diets, a deficit linked to chronic inflammation, poor gut health, and metabolic disease. One Bio, a Sacramento-based biotech spinout from UC Davis, is betting its proprietary processing platform can make that penalty disappear.
Its product, called WholeFibers™, is a category of short-chain plant fibers derived from agricultural waste and other plant materials. The company’s core technical claim is that it can “chop up” polysaccharides into odorless, colorless, and tasteless oligosaccharides that food and beverage formulators can add at inclusion rates of 20 grams or more without impacting the final product’s taste or texture [Perplexity Sonar Pro Brief]. The goal is not just to add bulk, but to reintroduce what the company calls “active fibers”,bioavailable compounds designed to support the microbiome, modulate immune function, and reduce inflammation [Perplexity Sonar Pro Brief]. For One Bio, the $27 million Series A round it closed in December 2024, led by Alpha Edison, is a vote of confidence that its invisible ingredient can become a standard in functional food formulation [AgFunderNews, December 2024].
The Wedge of Imperceptibility
One Bio’s market entry hinges on a simple but difficult technical proposition: deliver a high-dose, functional health ingredient that consumers cannot detect. This addresses a fundamental tension in the food industry. Consumers say they want healthier options, but they consistently reject products that sacrifice flavor or texture. Most existing fiber additives, like inulin or resistant starch, have inclusion limits before they negatively alter a product’s sensory profile.
WholeFibers are engineered to sidestep that trade-off. The company processes fibers from sources like seeds, nuts, fruits, and agricultural byproducts into short-chain oligosaccharides that are, by design, flavorless and invisible [Crunchbase]. This allows food companies to market products with meaningful fiber content,targeting gut health, immune support, or the booming market for “GLP-1 friendly” foods,without asking consumers to compromise on taste [thespoon.tech]. The platform approach is backed by what the company calls ‘The Glycopedia,’ a database mapping fiber structures to their fermentation pathways and biological effects, aiming to move from generic fiber fortification to targeted, evidence-based formulation [one.bio].
A Spinout with Strategic Backing
The company’s origins trace back to academic research at UC Davis, where it was founded in 2019 as BCD Bioscience [AgFunderNews, December 2024]. The scientific co-founders include Dr. Carlito Lebrilla, Dr. Bruce German, and Dr. David Mills, researchers with deep expertise in food science and microbiology. In 2023, the venture added a seasoned operator as co-founder and CEO: Matt Barnard, the co-founder of vertical farming company Plenty [AgFunderNews, December 2024]. His appointment signaled a shift from pure R&D toward commercial scaling and food industry partnerships.
The December 2024 Series A round attracted a mix of venture and strategic capital, underscoring the cross-sector interest in the technology.
| Investor | Type | Notable Focus |
|---|---|---|
| Alpha Edison | Venture Capital | Lead investor [AgFunderNews, December 2024] |
| Leaps by Bayer | Corporate Venture | Agtech and health impact investing |
| DSM-Firmenich | Strategic Corporate | Global ingredients and nutrition leader |
| Mitsui E12 | Corporate Venture | Japanese trading and investment house |
| Acre Venture Partners | Venture Capital | Existing investor, focused on food systems |
The participation of Bayer’s impact arm and a major ingredients player like DSM-Firmenich points to potential applications beyond consumer packaged goods, including agriculture and biopharmaceuticals, where novel oligosaccharides could play a role in modulating immune function [Perplexity Sonar Pro Brief].
The Regulatory and Commercial Landscape
One Bio operates in a space where health claims are tightly regulated. Its fibers are positioned as food ingredients, not drugs, which allows a faster path to market. The company will need to build its case through Generally Recognized as Safe (GRAS) determinations for its various fiber sources and, eventually, pursue structure/function claims about gut health with the FDA. The involvement of established strategic investors likely provides both credibility and guidance through this complex regulatory environment.
On the commercial front, the company is targeting formulators in food, beverage, and supplements. The immediate tailwind is the consumer shift toward functional nutrition and the specific demand for foods compatible with GLP-1 weight-loss medications, which often require high-protein, high-fiber diets to manage side effects [thespoon.tech]. By offering a fiber that doesn’t require a recipe overhaul, One Bio aims to lower the barrier for brands to create products for this growing demographic.
The company is actively hiring, with open roles for a Pilot Plant Operator in Sacramento, indicating it is moving from lab-scale production toward commercial manufacturing [LinkedIn]. This post-funding expansion is a critical next step to serving potential enterprise customers.
The Risks on the Shelf
For all its technical promise, One Bio faces a crowded and competitive landscape for functional ingredients. The success of its bet rests on several unproven assumptions.
- Commercial adoption at scale. While the science of short-chain fibers is sound, convincing large, conservative food companies to reformulate flagship products with a new, premium-priced ingredient is a long sales cycle. Traction with early-adopter brands will be the first real proof point.
- Cost and supply chain. Sourcing and processing agricultural waste into a pure, consistent, and flavorless ingredient at a cost that food manufacturers will accept is a significant operational challenge. The pilot plant phase will test these economics.
- Scientific differentiation. The company’s Glycopedia database and targeted health effects are a potential moat. However, without published, peer-reviewed clinical data specifically on WholeFibers, the health claims remain preliminary. The standard of evidence for microbiome modulation is rising.
The most credible near-term risk is that, despite the technical achievement, food brands may opt for cheaper, established fibers and accept lower inclusion rates, viewing One Bio’s offering as a premium niche ingredient rather than a category-redefining staple.
The Patient in the Aisle
For the individual consumer, the promise of One Bio’s technology is a world where everyday foods,from bread and pasta to snacks and beverages,contribute meaningfully to gut health without a sensory tax. The target patient population is broad: anyone with a fiber-deficient diet, which includes a majority of adults in industrialized nations. This deficiency is linked to higher risks for conditions like inflammatory bowel disease, type 2 diabetes, and certain cardiovascular ailments.
The standard of care today is a conscious, often burdensome, effort to compensate. It involves seeking out specialty high-fiber products that may be less palatable, taking fiber supplements, or meticulously planning meals around whole grains, legumes, and vegetables. For many, this regimen is unsustainable. One Bio’s vision is to make therapeutic fiber intake passive and imperceptible, baked into the processed foods that already dominate the modern diet. It is a bet on making health invisible, and for the millions navigating metabolic and inflammatory conditions, that invisibility could be the most valuable feature of all.
Sources
- [AgFunderNews, December 2024] UC Davis spinoff One Bio raises $27m Series A to bridge the fiber gap | https://agfundernews.com/uc-davis-spinoff-one-bio-raises-27m-series-a-to-bridge-the-fiber-gap
- [Perplexity Sonar Pro Brief] One Bio company overview and technology description
- [Crunchbase] one.bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/one-bio
- [thespoon.tech] One Bio Raises $27M to Advance Short-Chain Fiber Ingredients for GLP-1 Friendly Foods | https://thespoon.tech/one-bio-raises-27m-to-advance-short-chain-fiber-for-glp-1-friendly-foods/
- [one.bio] About | One BIO | https://one.bio/about/
- [LinkedIn] one.bio hiring Pilot Plant Operator in Sacramento, CA | https://www.linkedin.com/jobs/view/pilot-plant-operator-at-one-bio-4166528231